- Home
- Software Solutions
- Resources
- Corporate
Bevacizumab and Abraxane as Second-Line Therapy in Triple Negative Metastatic Breast Cancer
Sponsors:
| Phases:
| |
| Indications | Acronym: | |
| ||
Age Groups:
| Gender: Female | |
Names:
| Enrollment: 37 | |
Additional information about NCT00472693.